Sahajanand Medical Technologies’ Rs 475.48 crore IPO reached 1.34 times subscription by mid-day on October 19. The offer is entirely an offer for sale by existing shareholders, with solid participation from institutional investors in the anchor round. The company specializes in cardiovascular devices, including stents and TAVI systems.
The initial public offering (IPO) of Sahajanand Medical Technologies saw early traction on October 19, with investors placing bids for 1.34 times the available shares. National Stock Exchange data showed that non-institutional investors were the most active, bidding for 1.8 times the shares reserved for them, while retail participation stood at 1.32 times.
Sahajanand Medical Technologies operates in the high-tech medical device sector, manufacturing coronary stents, balloons, and TAVI (transcatheter aortic valve implantation) systems. These products are critical for heart-related treatments and require constant innovation and strict regulatory compliance. The company’s ability to maintain its market position against global competitors remains a core aspect of its business profile.
A key detail for investors to note is that the entire Rs 475.48 crore offering is an offer for sale (OFS). In an OFS, shares are sold by existing shareholders rather than the company issuing new shares. This means the money raised through this IPO will go to the selling shareholders instead of being used by the company for new business projects or expansion.
Before opening to the public, the company secured Rs 140.06 crore from anchor investors, signaling institutional interest. Major participants included mutual fund houses like Nippon Life India, DSP Mutual Fund, WhiteOak Capital, Invesco India, and UTI AMC, alongside entities like Tata AIA Life Insurance. Institutional backing is often viewed by the market as a sign of confidence in the company’s financial stability and business model.
While early subscription numbers are positive, investors should be aware that the medical device sector is highly competitive. The company faces ongoing pressure from large multinational corporations that dominate the cardiovascular space. Furthermore, the grey market premium, which showed an 8 percent gain, is an unofficial indicator and does not guarantee how the stock will perform on the day of listing. Pricing, regulatory changes, and healthcare demand are significant factors that will shape the company’s future performance.
The public offering is being managed by a team of merchant bankers, including Motilal Oswal Investment Advisors, Avendus Capital, HSBC Securities and Capital Markets (India), and Nuvama Wealth Management. Investors will now watch for the final subscription data as the offering window progresses toward closing, which will provide a clearer picture of overall demand.